Bankers Won't Push Valeant Pharma (VRX) into Default - OPI
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- S&P 500, Dow futures inch up as MidEast hopes offset SpaceX, AMD drag
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
Valeant Pharma (VRX) Weakens Heading into Market Close, Shares Down 11.75%
March 17, 2016 3:55 PM EDTValeant Pharma (NYSE: VRX) Weakens Heading into Market Close, Shares Down 11.75%
... MoreValeant Pharma (VRX) Bloodletting Continues; Shares Down 10%
March 17, 2016 11:23 AM EDTValeant Pharma (NYSE: VRX) bloodletting continues. Shares now down 10%.
... MoreBMO Sees a Path To Credibility for Valeant Pharma (VRX)
March 17, 2016 6:48 AM EDTMarket Perform price target of $66.00 (from $133.00)
BMO Capital analyst, Alex Arfaei believes Valeant Pharmaceuticals (NYSE: VRX) management needs to regain credibility and lays out 5 steps to accomplish that task. No change to the Market Perform rating but the PT drops to $66 (from $133).
Valeants management was... More
Exclusive: Valeant lenders to prepare tough demands for default talks – sources
March 17, 2016 1:07 AM EDTBy Kristen Haunss and Carl O'Donnell
NEW YORK (LPC/Reuters) - Creditors of Valeant Pharmaceuticals International (NYSE: VRX) (NYSE: VRX), which has been in violation of lender agreements since Wednesday, are beginning to demand new terms that could further pressure the drugmaker's business model, according to three people familiar with the matter.
Valeant said on Tuesday it would not meet a March 15 deadline for filing its annual financial statements with securities regulators, putting it in danger of defaulting on its $30 billion debt load. Valeant also sharply reduced its... More
Valeant Pharma (VRX) Rating Suspended at Evercore ISI
March 16, 2016 5:21 PM EDTValeant Pharma (NYSE: VRX) Rating Suspended at Evercore ISI
... MoreValeant Pharma (VRX) Gains on Ackman Chatter
March 16, 2016 5:10 PM EDTValeant Pharma (NYSE: VRX) ticks higher after-hours on word Bill Ackman is selling some of his Mondelez Int'l (NASDAQ: MDLZ) stake. Speculators believe he could be using the funds to buy more Valeant stock.
Shares of VRX are up 0.2% after-hours to $33.60.
... More